Anjalina Mitra and Agatha Cimbalova promoted

Anjalina Mitra, Consultant (L) and Agatha Cimbalova, Consultant (R)

Windrose are excited to announce two promotions in our London office.

Anjalina Mitra and Agatha Cimbalova have both been promoted to Consultant, after making huge progress in their Senior Analyst roles.

In her Senior Analyst role, Anjie supported multiple engagements to support the launch of vaccines and drugs across the globe, looking at commercial and pricing opportunities, as well as optimizing the launch sequence for better P&MA outcomes. She also played a crucial role in continuing to build and grow the Windrose team through her ongoing commitment to the recruiting activities.

Over the past two years, Agatha has honed her strategic consulting skills, having worked on many projects across multiple therapy areas, including: oncology, women’s health, inflammation, and vaccines. She has been a leader within Windrose team, mentoring the junior team and contributing to firm building initiatives, as well as helping to organize fun social events.

Congratulations to Anjie and Agatha, who have shown fantastic career advancement.


What’s it like to work at Windrose?

We understand how important it is to continuously enable our team's growth and development. Windrose team members get to work on diverse projects, grow their professional experience, and build meaningful relationships.

  • We grow the firm by growing our people. Many of our senior team have been at Windrose since its inception.

  • We are strengthened by continuous feedback throughout the year.

  • We are constantly learning and seeking new development opportunities.

  • We work together with respect and integrity.

  • We value diversity and encourage differing opinions.

  • We respect work-life balance while considering our clients’ needs.

  • We judge performance based on merit alone.

Visit our Careers page to find out more >

Previous
Previous

New Starters in London: Ioana Vitan and James O’Brien

Next
Next

Global News Roundup: Q3 2022